Volver a Agenda
Session Chair(s)
Christine Blazynski, PHD
Chief Science Officer and Senior Vice President
Citeline, Inc., United States
Learning Objective : Evaluate industry's successes and failures in developing drugs that address rare and orphan diseases; Discuss failed and/or abandoned efforts in this therapeutic area; Report on current development pipeline and high interest versus low interest diseases.
Speaker(s)
When Your Company Adopts an Orphan Drug
Robin Winter-Sperry, MD
Scientific Resilience, United States
Global Medical Affairs
Industry Trends, Successes and Failures in Orphan and Rare Disease Therapeutics
Christine Blazynski, PHD
Citeline, Inc., United States
Chief Science Officer and Senior Vice President
¿Tiene una cuenta?